Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Tibial Delayed Healing Pivotal Clinical Trial

7 gennaio 2015 aggiornato da: Medtronic Spinal and Biologics

A Prospective, Randomized, Multicenter Pivotal Clinical Trial of the INFUSE/MASTERGRAFT™ Delayed Healing Device With Rigid Internal Fixation in the Treatment of Tibial Delayed Healing

Evaluate the INFUSE/MASTERGRAFT™ Delayed Healing Device as an alternative/replacement to autograft in the treatment of tibial delayed healing.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The purpose of this study is to evaluate the INFUSE/MASTERGRAFT™ Delayed Healing Device as an alternative/replacement to autograft in the treatment of tibial delayed healing. A subject will be considered to have tibial delayed healing when he/she is at least six months from the date of the most recent surgical intervention and has shown no signs of radiographic healing for at least three months. Radiographic signs of healing for this study are defined as either the progressive disappearance of fracture lines or the development of cortical continuity [bridging bone] at the site. All prospective patients must require surgical treatment with rigid internal fixation [reamed IM nail or plate/screws] and bone grafting.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

23

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Stati Uniti
    • Colorado
      • Denver, Colorado, Stati Uniti, 80204
        • Denver Health
    • Florida
      • Ft. Lauderdale, Florida, Stati Uniti, 33316
        • Shrock Orthopedic Research
      • Jacksonville, Florida, Stati Uniti, 32209
        • University of Florida College of Medicine
      • Orlando, Florida, Stati Uniti, 32806
        • Orlando Health
    • Indiana
      • Fort Wayne, Indiana, Stati Uniti, 46804
        • Fort Wayne Orthopaedics
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Methodist Hospital
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21215
        • Sinai Hospital of Baltimore
    • Michigan
      • Royal Oak, Michigan, Stati Uniti, 48073
        • William Beaumont Hospital
    • Missouri
      • Columbia, Missouri, Stati Uniti, 65201
        • University of Missouri
      • St. Louis, Missouri, Stati Uniti, 63104
        • St. Louis University Hospital
    • New York
      • Brooklyn, New York, Stati Uniti, 11220
        • Lutheran Medical Center
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Carolinas Medical Center
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43215
        • Ohio Health Research Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • University of Oklahoma
    • Pennsylvania
      • Danville, Pennsylvania, Stati Uniti, 17822
        • Geisinger Clinic
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Vanderbilt University Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

21 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Has tibial delayed healing. A subject will be considered to have delayed healing when he/she is at least six months from the date of the most recent surgical intervention and has shown no signs of radiographic healing for at least three months. (Radiographic signs of healing for this study are defined as either the progressive disappearance of fracture lines or the development of cortical continuity [bridging bone] at the site.)
  2. Has delayed healing of the tibia that requires treatment with rigid internal fixation and bone grafting. (Stable rigid internal fixation hardware may already be in place prior to treatment. If required, the fixation hardware may be removed and replaced along with the placement of the bone graft.)
  3. Has adequate soft tissue coverage at the delayed healing site. All prior soft tissue coverage procedures (e.g., skin grafts or flaps) should be sufficiently healed for placement of a bone graft prior to enrollment in the study.
  4. Has a sufficient amount of iliac crest autograft available for a bone grafting procedure.
  5. After walking 5 or 6 steps, has intensity of pain/discomfort at the injury site equal to or greater than 4 (as reported on the preoperative Delayed Healing Site Pain Questionnaire form; 0 being no pain and 10 being pain as bad as it could be).
  6. Is at least 21 years of age and skeletally mature at the time of surgery.
  7. If a female of child-bearing potential, patient is not pregnant or nursing and agrees not to become pregnant for one year following surgery in the study.
  8. Is willing and able to comply with the study plan and able to understand and sign the Patient Informed Consent Form.

Exclusion Criteria:

  1. Has a congenital pseudarthrosis or pathological fracture nonunion (not including osteoporosis-related fractures).
  2. Has a tibial delayed healing with articular involvement (e.g., intra-articular). (The original fracture may have involved the joint, but the resulting delayed healing site may not involve the joint.)
  3. Has hypertrophic tibial delayed healing (e.g., observed on x-ray as having an abundant callus or "horse hoof" appearance).
  4. Has inadequate neurovascular status in the involved limb that may jeopardize healing.
  5. Has an active or a known prior infection at the delayed healing site (e.g., the presence of purulent drainage from the site, prior positive cultures from the site, or evidence of active/prior osteomyelitis at the site). Enrolled subjects whose intra-operative cultures test positive for bacteria may remain in the study.
  6. Has existing stable hardware that will not be removed and does not meet the algorithm requirements.
  7. Has treatment planned for the delayed healing that does NOT include placement of a bone graft and/or rigid internal fixation consisting of a reamed intramedullary nail or plate/screws.
  8. Has a tibial delayed healing injury site with a bony defect larger than 4 cm in length.
  9. Has another injury/condition that prevents ambulation or completion of any of the study assessments.
  10. Has a history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, hyperthyroidism, parathyroid hormone disorder, Ehler-Danlos syndrome, osteogenesis imperfecta, calcium imbalance).
  11. Has a Vitamin D deficiency, defined as a 25-hydroxy Vitamin D serum concentration of ≤11ng/mL .
  12. Has an active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).
  13. Has an overt or active systemic infection (e.g., HIV/AIDS, hepatitis, bacteremia).
  14. Has been on oral or injectable steroids for six weeks or more at time of enrollment. This does not include episodic steroid use; inhaled steroids; or steroid medication (e.g., Epidural Steroid Injections, Medrol DosePaks) specifically for the perioperative management of symptoms.
  15. Has a condition requiring postoperative medications that could interfere with bone healing of the implant, such as steroids. This does not include low dose aspirin for prophylactic anticoagulation; routine perioperative anti-inflammatory drugs; episodic steroid use; or inhaled steroids.
  16. Has a history of certain autoimmune diseases. (Refer to the List of Autoimmune Diseases in the CIP for further information.)
  17. Has a history of exposure to injectable collagen or silicone implants.
  18. Has any previous exposure to any recombinant BMPs of either human or animal extraction.
  19. Has a history of hypersensitivity to collagen or protein pharmaceuticals (e.g., monoclonal antibodies or gamma globulins).
  20. Has a history of allergy to bovine collagen products.
  21. Has a documented allergy or intolerance to metal or metal alloys, such as stainless steel or titanium.
  22. Has chronic or acute renal and/or hepatic failure or prior history of renal and/or hepatic parenchymal disease.
  23. Is mentally incompetent. If questionable, obtain psychiatric consult.
  24. Is a prisoner.
  25. Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse.
  26. Has received treatment with an investigational therapy (drug, device, and/or biologic) within 28 days prior to implantation surgery or such treatment is planned during the 12-month period following the study surgery

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: INFUSE/MASTERGRAFT
Patients received INFUSE/MASTERGRAFT granules with rigid internal fixation.
Dispositivo: INFUSE/MASTERGRAFT
INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
Altri nomi:
  • INFUSE
  • MASTERGRAFT
Comparatore attivo: Autograft bone
Patients received autograft bone with rigid internal fixation.
Procedura: Autograft bone
Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
Altri nomi:
  • Innesto osseo autologo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Success
Lasso di tempo: 12 Months
Overall success is reported as participants who met all of the following criteria: 1. radiographic union success; 2. success in weight bearing ability; 3. improvement in pain at the delayed healing site; 4. no serious adverse event classified as "implant-associated" or "implant/surgical procedure-associated" (device-related); 5.no additional surgical procedures classified as a failure.
12 Months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Radiographic Union Success
Lasso di tempo: 12 months
Radiographic union success (a component of overall success) was defined as complete disappearance of fracture lines or the presence of bridging bone across the delayed healing site as observed on at least three of the four cortices (anterior, posterior, medial, and lateral), using plain films. If there was more than one delayed healing fracture line, all fracture lines must have been united in order to be considered a successful fracture union.
12 months
Success in Weight Bearing Ability
Lasso di tempo: 12 months
Success in weight bearing ability (a component of overall success) was defined that subject was able to bear weight without severe pain on the affected limb. The subject was asked to stand, bearing full weight on the affected limb in a single-leg stance without ambulatory assistance for 10 seconds. If the subject was able to do so without severe pain, a positive (success) response was recorded. If the subject was either unable to stand on the affected limb in a single-leg stance or declined to do so because of limb weakness, poor balance, or severe leg pain, a negative (failure) response was documented.
12 months
Success of Pain Status at the Delayed Healing Site
Lasso di tempo: 12 months
After walking five or six steps, subjects rated their intensity of pain/discomfort at the delayed healing site using a numerical rating scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be". Subjects who were unable or declined to walk because of severe leg pain were considered to have a score of 10. Success for pain at the delayed healing site was defined as at least a 2-point improvement in pain from the pre-operative score. Success of pain status at the delayed healing site was a component of overall success.
12 months
Success in Short Musculoskeletal Functional Assessment (SMFA)
Lasso di tempo: 12 months
The SMFA is an assessment tool that measures a subject's overall function for a broad range of musculoskeletal injuries and disorders. The SMFA results were summarized into two components, the dysfunctional index and the bother index. Success for the SMFA assessment was defined as any improvement post-operatively as compared to the pre-operative condition.
12 months
Success in Short Form 36-Item (SF-36) Health Survey
Lasso di tempo: 12 months
SF-36 was used to assess general health status. The SF-36 results were summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). Success was defined as any improvement in a subject's SF-36 PCS post-operatively as compared to the pre-operative condition.
12 months
Number of Subjects Having Additional Surgical Procedure Classified as a Treatment "Failure"
Lasso di tempo: 12 months
Subject who had a surgery after the original study treatment was classified as a treatment "failure" if the additional surgery or treatment occurred in the involved limb and affected the study treatment and/or its mechanism of action in relation to the diagnosis or condition of the subject that was the cause for having the original study treatment.
12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Medtronic Spinal and Biologics

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 novembre 2010

Completamento primario (Effettivo)

1 ottobre 2013

Completamento dello studio (Effettivo)

1 dicembre 2013

Date di iscrizione allo studio

Primo inviato

17 novembre 2009

Primo inviato che soddisfa i criteri di controllo qualità

17 novembre 2009

Primo Inserito (Stima)

18 novembre 2009

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

21 gennaio 2015

Ultimo aggiornamento inviato che soddisfa i criteri QC

7 gennaio 2015

Ultimo verificato

1 gennaio 2015

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • Medtronic P07-01

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su INFUSE/MASTERGRAFT

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Ecuador

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi